Efficacy of the Mirasol pathogen reduction technology system against severe fever with thrombocytopenia syndrome virus (SFTSV)

Vox Sang. 2015 Nov;109(4):417-9. doi: 10.1111/vox.12305. Epub 2015 Jun 1.

Abstract

Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tickborne virus in the Bunyaviridae family. This virus has recently been found in China, Japan and Korea. The risk of transfusion-transmitted SFTSV infection (TTI-SFTSV) is a concern because person-to-person transmission resulting from contact with SFTSV-contaminated blood has been reported. Therefore, we investigated the efficacy of the Mirasol pathogen reduction technology (PRT) system for inactivating SFTSV in vitro. The Mirasol PRT system achieved a > 4.11 log10 reduction value (LRV) for SFTSV. In conclusion, we showed that the Mirasol PRT system could potentially be used to reduce the risk of TTI-SFTSV.

Keywords: Mirasol PRT System; pathogen reduction technology; platelet concentrate; severe fever with thrombocytopenia.

MeSH terms

  • Antiviral Agents / pharmacology
  • Blood Safety / instrumentation
  • Blood Safety / methods*
  • Humans
  • Phlebovirus / drug effects*
  • Phlebovirus / radiation effects
  • Ultraviolet Rays

Substances

  • Antiviral Agents